Sr Director
Pfizer
Katty Wan is Senior Director and Small Molecule Group Lead in the Clinical Bioanalytics (CBx) Group within Translational Clinical Sciences. In this role, Katty oversees a team responsible for clinical PK, DDI-indicating biomarkers and specialty assays using liquid chromatography coupled with mass spectrometric (LCMS) measurements. Katty’s team supports small molecules, ADCs, nanoparticles and biotherapeutics if the assay is amendable to LCMS platform. This analytical support spans all stages of clinical development, all therapeutic areas (except vaccines), assay development and validation, sample analysis, reporting and registration. During her tenure, Katty’s team has successfully supported registration and approval of Ibrance, Vyndaqel, Xeljanz, Eucrisa, Braftovi, Talzenna, Xtandi, Vizimpro, Xalkori, Lorbrena, Bosulif, Steglatro, Paxlovid, Cibinqo, Tukysa, Zavzpret, Litfulo, Velsipity, Inlyta, Protonix, and Eliquis.
Katty is passionate about patient centric microsampling. She is representing Pfizer on multiple industry working groups (including AAPS, ASCPT, IHI COMFORT and PCSIG) to push for broader implementation of PCS in clinical settings.
Prior to joining the CBx, Katty worked in regulated Bioanalysis group in DMPK at Abbvie for 18 years. She has led method development team and principal investigator group. She mentored many scientists and served as DMPK rep for venetoclax. Her team supported approval of Zemplar, Kaletra, Venetoclax, Viekira pak, Mavyret and Rinvoq.
Friday, May 30, 2025
3:00 PM - 4:00 PM East Coast USA Time